Bisphosphonates and metastatic bone disease

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Barni, Sandro ^a   Mandala M ^a   Cazzaniga, M ^a   Cabiddu, M ^a   Cremonesi, M ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOCETAXEL; FULVESTRANT; IBANDRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; INCIDENCE; JAW DISEASE; LUNG CANCER; MORBIDITY; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VERTEBRA FRACTURE; VERTEBRA MALFORMATION;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; JAW DISEASES; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; OSTEOLYSIS; OSTEONECROSIS; OSTEOSCLEROSIS;

EID: 33645799699     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj935     Document Type: Article

References (37)

1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
2. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004 Jul 28; 292: 490-495.
3. Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2004; 2: 295-301.
4. Clézardin P, Ebetino FH, Pierrick GJ. Fournier bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res 2005; 65: 4971-4974.
5. Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol 2004; 31: 59-63.
6. Paterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
7. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: A randomized study. J Intern Med 1999; 246: 67-74.
8. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001; 88: 701-707.
9. Lahtinen R, Laakso M, Palva I et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-1052.
10. Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 1994; 87: 725-729.
11. McCloskey EV, MacLennan IC, Drayson MT et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 100: 317-325.
12. McCloskey EV, Dunn JA, Kanis JA et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma, Br J Haematol 2001; 113: 1035-1043.
13. Ernst D, Tannock I, Venner P et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 2002; (suppl; abstr 705).
14. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854.
15. Hortobagyi GN. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-1791.
16. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082-1090.
17. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-493.
18. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.
19. Djulbegovic B, Wheatley K, Ross J et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; 3: CD003188.
20. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
21. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 Aug 15; 21(16): 3150-3157.
22. Van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698-705.
23. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890-3894.
24. Magnetto S, Boissier S, Delmas PD et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83: 263-269.
25. Journe F, Chaboteaux C, Laurent G et al. Ibandronate inhibits the proliferation of estrogen receptor-positive breast cancer cells: evidence for additivity with antiestrogens. Bone 2004; 34: S59 (Abstr 23).
26. Fromigue O, Kheddoumi N, Body J-J. Bisphosphonates antagonize bone growth factors' effects on human breast cancer cells survival. Br J Cancer 2003; 89: 178-184.
27. Yacatan GJ, Poynor WJ, Talbert RL et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1998; 31: 402-410.
28. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137.
29. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405.
30. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: A pilot study. J Clin Oncol 2004; 22: 3587-3592.
31. Green JR, Seltenmeyer Y, Jaeggi KA et al. Renal tolerability profile of novel, potent bisphopshonates in two short-term rat models. Pharmacol Toxicol 1997; 80: 225-230.
32. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003; 191: 159-167.
33. Pfister T, Atzpodien E, Bohrmann B et al. Acute nephotoxicity of three intravenous bisphopshonates in the rat. Basic Clin Pharmacol Toxicol 2005 (in press).
34. Von Moos R. bisphosphonate treatment recommendations for oncologists. The Oncologist 2005; 10: 19-24.
35. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. J Clin Oncol 2000; 12: 1378-1391.
36. Migliorati CA, Schubert MM, Peterson DE et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 2005; 104: 83-93.
37. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587.